A placebo-controlled, first-in-human phase I study of the anti-ADAMTS-5 nanobody M-6495 Nov. 19, 2019
3SBio and Verseau select VTX-0811 as first licensed program under immuno-oncology partnership Nov. 19, 2019
First placebo-controlled trial in renal scleroderma shows positive results for zibotentan Nov. 19, 2019
Differentially expressed sncRNAs in patients with T1D at risk of progressive renal disease Nov. 19, 2019
Effluent DcR2 is a new marker of peritoneal fibrosis in patients with peritoneal dialysis Nov. 19, 2019
RSS